GSK CEO: Drug Discovery, AI in Pharma, and Changing Company Culture
Listen to the original audio · Transcribed with NVIDIA Parakeet · Why times can differ in your player
Mm. Hi everyone, I'm Nikola Tanyan, the CEO of the Norwegian Soviet Wealth Fund. And today I'm in really good company with Emma Walmsley, the CEO of GSK. One of the global leaders in pharmaceuticals. Now we own one point seven percent of GSK valued at one point three billion US dollars. Emma, great to have you here. Wonderful to be here. Thanks for having me. And I believe this is the second podcast ever in your life. Second ever. Wow. Looking forward uh very much to the conversation.
Mm. Now which areas of research excites you the most just now. Uh well
I'm excited about a lot of the ways that research, both in science and technology, are advancing, and particularly those two things together. I mean it is literally the point of our company is to innovate and that's where we allocate most of our capital. So in fact since I've been in this job I think we've nearly doubled our R and D spend. uh organically, and then of course opened up a huge amount of partnerships that we do externally and business development. To supplement the pipeline. Um
We already have this episode, so unlocking it is cheap and permanent: the full transcript (55 minutes, 9,219 words), segment and word-level timestamps, and .txt, .srt, .vtt and word-level JSON downloads, as many times as you like, forever.
No account needed, we create one from your checkout email. With credits it is 1 credit; packs start at 5 episodes for $3.49, and monthly plans are cheaper still.